Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072258 | 0.84 | CES2 (0.38) | CES2ARCACNA1HCACNA1CEGLN1 | |
| SCHEMBL18242578 | 0.78 | CES2 (0.38) | CES2ARCACNA1HCACNA1CEGLN1 | |
| SCHEMBL16405335 | 0.77 | RAPGEF4 (0.35) | CES2ARCACNA1HCACNA1CEGLN1 | |
| SCHEMBL4088512 | 0.77 | CES2 (0.39) | CES2ARCACNA1HCACNA1CCACNA1B | |
| SCHEMBL18242293 | 0.75 | CES2 (0.38) | CES2ARCACNA1HCACNA1CEGLN1 | |
| SCHEMBL21139491 | 0.75 | PDE2A (0.44) | PDE2A | |
| SCHEMBL13799252 | 0.75 | PDE2A (0.33) | CES2ARCACNA1HCACNA1CEGLN1 | |
| SCHEMBL21139479 | 0.75 | PDE2A (0.41) | CES2ARCACNA1HCACNA1CEGLN1 | |
| SCHEMBL20072377 | 0.74 | PDE2A (0.47) | CES2ARPDE2AHTR2AHTR2C | |
| SCHEMBL25982617 | 0.74 | AR (0.40) | CES2ARCACNA1HCACNA1CEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-18 | — | — | US | disclosed |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | PHGDH, PGD, PGK1 | CES2 4002/4885AR 1831/4885CACNA1H 2948/4885 |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | PHGDH, PGD, PGK1 | CES2 3921/4885AR 1406/4885CACNA1H 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.